SOPHiA GENETICS S.A.
NASDAQ:SOPHMedical - Healthcare Information Services
+$0.02 today
- Market cap
- $635.90M
- Beta
- 0.98
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.14
Volume 0.61M
Average 0.10M
SOPH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
SOPHiA GENETICS S.A.NASDAQ: SOPH
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows in line with its trailing trend
Q1 FY2026 research & development of $9.46M rose 3.8% year over year, behind the +5.3% change in trailing-twelve-month research & development. Sequentially, it rose 10.8% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.
Context
- Research & development amounted to 43.4% of revenue in FY2025, down 9.3 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3.8% toward the trailing-twelve-month pace of +5.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 33.57M USD
- Year-over-year change
- -2.3%
- 4-year CAGR
- +6.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.57M | -2.3% |
| FY2024 | 2024-12-31 | 34.37M | -7.0% |
| FY2023 | 2023-12-31 | 36.97M | +4.5% |
| FY2022 | 2022-12-31 | 35.37M | +33.1% |
| FY2021 | 2021-12-31 | 26.58M | — |
Research & Development vs competitors
How SOPH compares with its peers on the latest reported figures
- SOPH's LTM Mar 2026 research & development of $35.89M is the 7th highest of the 10 companies compared; the peer median is $44.26M.
- Its year-over-year change of +5.3% is the 7th highest of 9, against a peer median of +10.1%.
- Research & development amounts to 44.2% of revenue for SOPH, versus a peer median of 14.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $327.05M | +12.8% | +25.3% | 21.7% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $59.21M | +38.6% | — | 14.9% |
| LTM Mar 2026 | $52.54M | +7.4% | +4.8% | 16.9% | |
| LTM Mar 2026 | $52.16M | +6.9% | -8.2% | 80.9% | |
| LTM Mar 2026 | $44.26M | -24.0% | -13.0% | 14.6% | |
| LTM Mar 2026 | $42.8M | +20.1% | +13.3% | 10.2% | |
| LTM Mar 2026 | $35.89M | +5.3% | -1.7% | 44.2% | |
| LTM Mar 2026 | $31.97M | -10.4% | -0.1% | 13.4% | |
| LTM Mar 2026 | $3.48M | +1276.3% | — | 3.2% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SOPH) | $44.26M | +10.1% | +2.4% | 14.6% | |
Competitors are the stored peer set for SOPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 40.45M | 47.56M | 62.37M | 65.17M | 77.27M |
| Cost of Revenue | 15.23M | 16.31M | 19.46M | 21.24M | 29.46M |
| Gross Profit | 25.22M | 31.25M | 42.91M | 43.94M | 47.81M |
| Gross Margin | 62.4% | 65.7% | 68.8% | 67.4% | 61.9% |
| Research & Development | 26.58M | 35.37M | 36.97M | 34.37M | 33.57M |
| Selling, General & Admin | 70.24M | 84.08M | 81.72M | 76.32M | 85.17M |
| Operating Expenses | 96.71M | 119.08M | 117.74M | 110.51M | 118.74M |
| Depreciation & Amortization | 3.61M | 5.57M | 8.34M | 8.6M | 9.53M |
| EBITDA | (69.24M) | (81.38M) | (69.57M) | (50.76M) | (64.4M) |
| EBITDA Margin | -171.2% | -171.1% | -111.5% | -77.9% | -83.3% |
| Operating Income | (71.49M) | (87.82M) | (74.83M) | (66.57M) | (70.93M) |
| Operating Margin | -176.7% | -184.7% | -120.0% | -102.1% | -91.8% |
| Interest Income | 20K | 1.32M | 4.55M | 3.36M | 1.87M |
| Interest Expense | 658K | 639K | 588K | 1.91M | 4.55M |
| Other Income / Expenses | (2.02M) | 238K | (3.67M) | 5.3M | (7.56M) |
| Income Before Tax | (73.51M) | (87.59M) | (78.5M) | (61.27M) | (78.49M) |
| Pre-Tax Margin | -181.7% | -184.2% | -125.9% | -94.0% | -101.6% |
| Income Tax Expense | 168K | (136K) | 486K | 1.22M | 512K |
| Net Income | (73.68M) | (87.45M) | (78.98M) | (62.49M) | (79M) |
| Net Margin | -182.1% | -183.9% | -126.6% | -95.9% | -102.2% |
| EPS (Basic) | (1.33) | (1.36) | (1.22) | (0.95) | (1.17) |
| EPS (Diluted) | (1.33) | (1.36) | (1.22) | (0.95) | (1.17) |
| Weighted Avg Shares | 55.3M | 64.1M | 64.75M | 65.78M | 67.54M |
| Weighted Avg Shares (Diluted) | 55.3M | 64.1M | 64.75M | 65.78M | 67.54M |
SOPHiA GENETICS S.A.
NASDAQ:SOPH
Intrinsic Alpha fair value
Locked
Current Price
$7.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.